Trials / Terminated
TerminatedNCT00505089
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
An Exploratory, Open Label Pharmacokinetic - Pharmacodynamic Study to Compare Subcutaneous Versus Intravenous Administration of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate the pharmacokinetic (PK) / total IL-1beta pharmacodynamic (PD) relationship in joint fluids of patients with rheumatoid arthritis (RA) treated with different doses of ACZ885 and to evaluate the impact of the subcutaneous (s.c.) versus intravenous (i.v.) route of administration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ACZ885 | |
| DRUG | ACZ885 | |
| DRUG | ACZ885 | |
| DRUG | ACZ885 |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-05-01
- First posted
- 2007-07-20
- Last updated
- 2009-08-25
Locations
9 sites across 4 countries: Belgium, Germany, Netherlands, Poland
Source: ClinicalTrials.gov record NCT00505089. Inclusion in this directory is not an endorsement.